AstraZeneca (HAM:ZEG) Construction In Progress: €0 Mil (As of Mar. 2026)


HAM:ZEG AstraZeneca PLC HAM:ZEG
87 GF Score
Price €165.90
GF Value €155.50
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is AstraZeneca Construction In Progress?

AstraZeneca HAM:ZEG +0.45% 87 Construction In Progress is €0 Mil as of Mar. 2026. GuruFocus rates HAM:ZEG with a GF Score™ of 87/100 and a GF Value™ of €155.50 (Fairly Valued). The stock has 5 warning signs investors should review.

AstraZeneca's quarterly construction in progress increased from Sep. 2025 (€0 Mil) to Dec. 2025 (€4,048 Mil) but then declined from Dec. 2025 (€4,048 Mil) to Mar. 2026 (€0 Mil).

AstraZeneca's annual construction in progress increased from Dec. 2023 (€1,875 Mil) to Dec. 2024 (€2,663 Mil) and increased from Dec. 2024 (€2,663 Mil) to Dec. 2025 (€4,048 Mil).

AstraZeneca Construction In Progress Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Construction In Progress Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,414.28 2,504.43 1,875.27 2,663.50 4,047.96

AstraZeneca Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 4,047.96 0.00
HAM:ZEG
87GF Score
AstraZeneca PLC HAM:ZEG
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0 Mil mean?
AstraZeneca (HAM:ZEG) has a Construction In Progress of €0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on AstraZeneca and its competitors.
Is AstraZeneca's Construction In Progress too high?
AstraZeneca's current Construction In Progress is €0 Mil. Overall, AstraZeneca has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Construction In Progress compare to LLY and JNJ?
AstraZeneca's Construction In Progress of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on AstraZeneca and its competitors. AstraZeneca's current Construction In Progress is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca (HAM:ZEG) is currently considered Fairly Valued. The stock's GF Value™ is €155.50, compared to a current price of €165.90 — trading 6.7% above its estimated fair value. The current Construction In Progress is €0 Mil. AstraZeneca's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For AstraZeneca (HAM:ZEG), the current Construction In Progress is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (HAM:ZEG) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be overvalued. The current stock price of €165.90 is trading 6.7% above its estimated GF Value™ of €155.50. GuruFocus considers AstraZeneca to be Fairly Valued.

Key valuation signals for HAM:ZEG:

  • Construction In Progress: €0 Mil
  • GF Value™: €155.50 vs. price of €165.90 (6.7% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the HAM:ZEG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
87GF Score

Get the complete analysis for HAM:ZEG

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€165.90
Price
€155.50
GF Value